Space LiinTech launches next-generation experiment module BEE-PC2 aboard SpaceX Falcon 9

Protein co-crystallization in microgravity to enable atomic-level analysis for SBDD

Commercial CRO service model enters validation phase, with CMO expansion on the horizon

A SpaceX Falcon 9 rocket stands on the launch pad at Cape Canaveral Space Force Station in Florida on Wednesday (local time). [Space LiinTech]
A SpaceX Falcon 9 rocket stands on the launch pad at Cape Canaveral Space Force Station in Florida on Wednesday (local time). [Space LiinTech]

The commercial validation of space-based drug discovery — using protein structures of hard-to-treat diseases mapped in the weightlessness of orbit — is gaining serious momentum in South Korea.

The effort has moved well beyond basic academic research or simple environmental exposure tests. The goal now is to build a commercial contract research organization, or CRO, service model that handles drug development on behalf of pharmaceutical and biotech companies.

Space LiinTech, a company specializing in space pharmaceuticals, announced Thursday that its AI-powered next-generation space drug experiment module, BEE-PC2, was successfully launched to the International Space Station aboard a SpaceX Falcon 9 rocket from Cape Canaveral Space Force Station in Florida on Wednesday (local time).

The launch was carried out under NASA's commercial cargo resupply mission CRS-35. Following BEE-PC1 — which Space LiinTech says was South Korea's first ISS space pharmaceutical experiment, conducted last year — the company plans to use this mission to fully validate the commercial foundation for a space protein crystallization CRO service aimed at pharmaceutical and biotech firms.

The centerpiece of BEE-PC2 is a co-crystallization experiment in which crystals are grown with a target protein bound to a small-molecule drug candidate. On Earth, gravity-driven sedimentation and buoyancy-induced convection make it difficult to grow large, uniform crystals of protein-compound complexes. In the microgravity environment of space, by contrast, conditions are far more favorable for growing high-purity protein crystals with fewer defects.

The company plans to retrieve the samples grown in space and compare them with ground controls through X-ray diffraction analysis. The data will be used to confirm, at the atomic level, how a drug candidate interacts with the binding site of a target protein — and to assess whether the results can inform structure-based drug design, or SBDD, which uses computational modeling of three-dimensional molecular structures to optimize and design new drug candidates.

Space LiinTech's space pharmaceutical experiment module BEE-PC2. [Space LiinTech]
Space LiinTech's space pharmaceutical experiment module BEE-PC2. [Space LiinTech]

The global pharmaceutical and biotech industry has already taken notice of microgravity-based drug research. US pharmaceutical company Merck (MSD) conducted research aboard the ISS to crystallize the active protein in its blockbuster immunotherapy drug Keytruda, obtaining high-purity crystals that were more uniform and had lower viscosity than those produced on the ground. Using that data, Merck identified a technical pathway to convert Keytruda from an intravenous formulation into a subcutaneous form that patients can self-administer.

Drawing on that precedent, Space LiinTech is working to build an integrated CRO model covering target protein selection, ground-based preliminary screening, in-orbit experiment operations, sample retrieval and structural analysis.

The company is expanding its research platform across two space missions launched days apart. It sent its independently developed 12U-class space pharmaceutical satellite BEE-1012 into orbit on Oct. 7 via the fifth launch of South Korea's Nuri rocket, then followed up six days later by sending the ISS module up through SpaceX.

The strategy divides work between two platforms: protein crystallization CRO research requiring precise analysis and rapid sample retrieval is conducted on the ISS under the BEE-PC series, while long-duration space exposure and pharmaceutical manufacturing process scale-up are handled by the independent BEE-1000 satellite series. Building on this dual-platform approach, the company plans to eventually expand into contract manufacturing, or CMO, producing pharmaceuticals directly in space in partnership with commercial space stations.

Government support for the company's research and development continues on multiple fronts. Space LiinTech is participating as a lead organization in the Ministry of Health and Welfare's Korean ARPA-H project and in the Ministry of SMEs and Startups' Deep Tech Challenge Project ecosystem innovation track, covering the first-stage proof-of-concept and proof-of-manufacturing phases. The company is also carrying out a manufacturing module development task under a small unmanned space manufacturing platform demonstration project led by the Korea AeroSpace Administration (KASA) and Seoul National University.

"If BEE-PC1 last year was the first demonstration that confirmed the potential of South Korea's space pharmaceutical technology, BEE-PC2 is an important step in developing that technology into a service that pharmaceutical and biotech companies can actually use," said Yoon Hak-soon, chief executive of Space LiinTech. "We will continue to expand our services so that global pharmaceutical companies can leverage the space environment for drug development, building on a space pharmaceutical platform that spans both the International Space Station and independent satellites."


silverpaper@heraldcorp.com